Dyne Therapeutics, Inc. (NASDAQ:DYN) Insider Oxana Beskrovnaya Sells 2,153 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Oxana Beskrovnaya sold 2,153 shares of Dyne Therapeutics stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $11.38, for a total transaction of $24,501.14. Following the completion of the transaction, the insider now directly owns 195,840 shares in the company, valued at approximately $2,228,659.20. The trade was a 1.09 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Oxana Beskrovnaya also recently made the following trade(s):

• On Tuesday, February 18th, Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10.

Dyne Therapeutics Stock Up 1.4 %

Shares of Dyne Therapeutics stock opened at $12.05 on Friday. The stock’s 50-day simple moving average is $14.83 and its 200-day simple moving average is $25.63. Dyne Therapeutics, Inc. has a 52 week low of $11.18 and a 52 week high of $47.45. The company has a market capitalization of $1.36 billion, a price-to-earnings ratio of -3.38 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. On average, equities analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on DYN. Chardan Capital reiterated a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a report on Friday, February 28th. Robert W. Baird initiated coverage on Dyne Therapeutics in a report on Friday, December 13th. They issued an “outperform” rating and a $46.00 price objective for the company. Raymond James upgraded Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. Finally, Baird R W upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $48.85.

Hedge Funds Weigh In On Dyne Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Quantbot Technologies LP purchased a new position in shares of Dyne Therapeutics during the third quarter valued at approximately $34,000. Point72 DIFC Ltd purchased a new position in Dyne Therapeutics during the 3rd quarter valued at $36,000. US Bancorp DE increased its stake in Dyne Therapeutics by 776.9% in the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after purchasing an additional 1,212 shares during the period. GF Fund Management CO. LTD. purchased a new position in Dyne Therapeutics in the 4th quarter worth about $50,000. Finally, KBC Group NV grew its stake in Dyne Therapeutics by 53.4% in the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock worth $77,000 after acquiring an additional 751 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.